Business
Amesite Announces Closing of Up To $7.8 Million Concurrent Registered Direct Offering and Private Placements Priced At-the-Market Under Nasdaq Rules
$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrantsDETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a
About this update from Amesite Inc.
[{"type":"image","alt":"Amesite Inc.","displaySize":"","headline":null,"caption":"Amesite Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/99ad0e7bb5d658f1ddb004c2e77004b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iquV3gU1Q.iJKdyEzVEzFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/99ad0e7bb5d658f1ddb004c2e77004b2","width":300,"height":88}},"lazy":false},{"type":"text","content":"$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants","length":128,"tagName":"p"},{"type":"text","content":"DETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors unregistered Series A-1 warrants to purchase up to 696,866 shares of common stock and unregistered Series A-2 warrants to purchase up to 696,866 shares of common stock. The warrants have an exercise price of $1.435 per share and will be exercisable beginning on the effective date of stockholder approval for the issuance of the shares issuable upon exercise of the warrants. The Series A-1 warrants will expire five years after the later of (i) effective date of the Resale Registration Statement (as defined below) and (ii) the date of stockholder approval and the Series A-2 warrants will expire eighteen months after the later of (i) effective date of the Resale Registration Statement (as defined below) and (ii) the date of stockholder approval.","length":1241,"tagName":"p"},{"type":"text","content":"The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 696,866 shares of common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 696,866 shares of the Company’s common stock and Series A-2 warrants to purchase up to 696,866 shares of the Company’s common stock at ...